Platycodin D
Based on 9 publication(s) in Google Scholar
Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.34%
- CAS No.: 58479-68-8
- Formule: C57H92O28
- Masse moléculaire:1225.32
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Glycoside Compound Library
HY-L042
-
Oxygen Sensing Compound Library
HY-L045
-
Medicine Food Homology Compound Library
HY-L055
-
Terpenoids Library
HY-L056
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Neuroprotective Compound Library
HY-L070
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Gut Microbial Metabolite Library
HY-L078
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Microbial Metabolite Library
HY-L084
-
Anti-Obesity Compound Library
HY-L087
-
Lipid Metabolism Compound Library
HY-L091
-
Glucose Metabolism Compound Library
HY-L092
-
Anti-Cancer Natural Product Library
HY-L107
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Pain-Related Compound Library
HY-L139
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library
HY-L223
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Platycodin D
More- Free Radic Biol Med. 2024 Nov 1:224:707-722. [Abstract]
- Eur J Pharmacol. 2023 Oct 5:956:175957. [Abstract]
- Int Immunopharmacol. 2023 Feb:115:109733. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Aug 21;1871(8):168026. [Abstract]
- BMC Cancer. 2025 Jul 1;25(1):1042. [Abstract]
- Chin J Integr Med. 2026 May 18. [Abstract]
- FEBS Lett. 2024 Dec;598(24):3053-3070. [Abstract]
- Exp Hematol. 2023 Jul:123:46-55.e1. [Abstract]
- Basic Clinical Medicine. 2023 Aug, 43(8): 1222-1228.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
IF
-
WB
Voir tous les produits spécifiques à Isoform AMPK
More
Activité biologique
AMPKα[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-15 | IC50 |
5.7 μM
Compound: 5
|
Antiproliferative activity against human HCT15 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HCT15 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 20939516] |
| HCT-15 | IC50 |
7.9 μM
Compound: 5
|
Antiproliferative activity against human HCT15/CL02 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HCT15/CL02 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 20939516] |
| HSC-T6 | IC50 |
1.77 μM
Compound: 147
|
Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 29353722] |
| MES-SA | IC50 |
3.9 μM
Compound: 5
|
Antiproliferative activity against human MESSA cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MESSA cells after 48 hrs by sulforhodamine B assay
|
[PMID: 20939516] |
| MES-SA/Dx5 | IC50 |
>10 μM
Compound: 5
|
Antiproliferative activity against human MESSA/DX5 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MESSA/DX5 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 20939516] |
Platycodin D (4 μM; 24 h) increases gene expressions of Ucp1, Pgc1a, Sirt3, Cytc, Nrf1 and Prdm16, and suppresses expressions of adipokine genes Fabp4, Adipoq, Lipin1 in 3T3-L1 adipocytes and FABP4, ADIPOQ and RESISTIN in hAMSCs[1]. Platycodin D (2 and 10 μM) suppresses lipid accumulation in murine and human adipocytes respectively[1]. Platycodin D suppresses the protein expressions of PPARγ and C/EBPα, and increases protein expressions of UCP1, PGC1α, SIRT3, CIDEA and LIPIN1[1]. Platycodin D (10 μM) inhibits lipid droplet formation, and reduces the expression of the FABP4 protein involved in lipid metabolism and the expressions of PPARγ and C/EBPα[2]. Platycodin D (10 μM; 0-7 d) recoveres CCND1 mRNA level and increases PPARδ level[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Genetically obese db/db mice[1]
-
Dosage:5 mg/kg
-
Administration:Oral administration; 5 mg/kg, 5 times per week for 5 weeks
-
Result:Significantly decreased body weight gain without affecting food intake of mice. Decreased the liver tissue weight and increased the weight of brown adipose tissue (BAT).
Chemical Information
-
CAS No. 58479-68-8
-
Appearance Solid
-
Masse moléculaire 1225.32
-
Formule C57H92O28
-
Color White to off-white
-
SMILES
O=C([C@]1(CCC(C)(C)C2)[C@]2([H])C3=CC[C@@]4([H])[C@@](C)(CC[C@]5([H])[C@@]4(C[C@H](O)[C@H](O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6CO)C5(CO)CO)C)[C@]3(C)C[C@H]1O)O[C@H](OC[C@H](O)[C@@H]7O)[C@@H]7O[C@@](O[C@@H](C)[C@H](O[C@@](OC[C@@H](O)[C@@H]8O[C@@](OC[C@]9(O)CO)([H])[C@@H]9O)([H])[C@@H]8O)[C@H]%10O)([H])[C@@H]%10O
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Free Radic Biol Med
Platycodin D ameliorates polycystic ovary syndrome-induced ovarian damage by upregulating CD44 to attenuate ferroptosis. [Abstract]2024 Nov 1:224:707-722. PMID: 39321891 -
Eur J Pharmacol
Platycodin D induces apoptotic cell death through PI3K/AKT and MAPK/ERK pathways and synergizes with venetoclax in acute myeloid leukemia. [Abstract]2023 Oct 5:956:175957. PMID: 37541375 -
Int Immunopharmacol
Platycodin D induces neutrophil apoptosis by downregulating PD-L1 expression to inhibit breast cancer pulmonary metastasis. [Abstract]2023 Feb:115:109733. PMID: 37724959
Platycodin D purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 Feb:115:109733. [Abstract]
Platycodin D (PlaD; 10, 20 mg/kg; i.g; once daily for 23 days) significantly inhibited tumor growth (fig B).The tumor inhibition rate is approximately 39 % in response to 10 mg/kg and 57 % in response to 20 mg/kg (fig C).
Platycodin D purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 Feb:115:109733. [Abstract]
Platycodin D (PlaD; 3.75, 5, 7.5, 10, 15, 20 μM; 24 h) dose-dependently inhibits the viability of dHL-60 cells.
Platycodin D purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 Feb:115:109733. [Abstract]
When the dHL-60 cells are treated with Platycodin D (PlaD; 0, 4, 8, 12 μM; 24 h), the numbers of migrated cells decreases significantly in a dose-dependent manner with or without IFN-γ induction.
Platycodin D purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 Feb:115:109733. [Abstract]
Platycodin D (PlaD; 4, 8, 12 μM) inhibits the high expression of PD-L1 in dHL-60 cells induced by IFN-γ (Fig. F and G).
-
Biochim Biophys Acta Mol Basis Dis
Platycodin D attenuates diabetic renal ischemia/reperfusion injury by enhancing mitophagy and suppressing MAPK/NF-κB signaling activation. [Abstract]2025 Aug 21;1871(8):168026. PMID: 40848991 -
BMC Cancer
Platycodin D-mediated METTL16 downregulation promotes docetaxel treatment of prostate cancer by regulating ferroptosis. [Abstract]2025 Jul 1;25(1):1042. PMID: 40597047 -
Chin J Integr Med
Platycodin D Overcomes Cisplatin Resistance in Gastric Cancer by Inducing Ferroptosis through TLK1-Dependent UHRF2/DNMT3A/ALOX15 Pathway. [Abstract]2026 May 18. PMID: 42149324 -
FEBS Lett
Platycodin D reduces PD-L1 levels by inhibiting LXR-β activity and combines with nintedanib to enhance the tumor-killing effect of T cells. [Abstract]2024 Dec;598(24):3053-3070. PMID: 39428320 -
Exp Hematol
Platycodin D induces proliferation inhibition and mitochondrial apoptosis in diffuse large B-cell lymphoma. [Abstract]2023 Jul:123:46-55.e1. PMID: 37085039 -
Solvant et solubilité
DMSO : 50 mg/mL (40.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.04 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.04 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Kim HL, et al. Platycodin D, a novel activator of AMP-activated protein kinase, attenuates obesity in db/db mice via regulation of adipogenesis and thermogenesis. Phytomedicine. 2019 Jan;52:254-263. [Content Brief]
[2]. Lee H, et al. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D, a natural compound found in Platycodon grandiflorum. Life Sci. 2011 Sep 12;89(11-12):388-94. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8161 mL | 4.0806 mL | 8.1611 mL | 20.4028 mL |
| 5 mM | 0.1632 mL | 0.8161 mL | 1.6322 mL | 4.0806 mL | |
| 10 mM | 0.0816 mL | 0.4081 mL | 0.8161 mL | 2.0403 mL | |
| 15 mM | 0.0544 mL | 0.2720 mL | 0.5441 mL | 1.3602 mL | |
| 20 mM | 0.0408 mL | 0.2040 mL | 0.4081 mL | 1.0201 mL | |
| 25 mM | 0.0326 mL | 0.1632 mL | 0.3264 mL | 0.8161 mL | |
| 30 mM | 0.0272 mL | 0.1360 mL | 0.2720 mL | 0.6801 mL | |
| 40 mM | 0.0204 mL | 0.1020 mL | 0.2040 mL | 0.5101 mL |
Platycodin D Related Classifications
HY-N1411 Related Classifications
Powered by Bioz